Kantaro’s SARS-CoV-2 IgG Antibody Test Kits

Our first diagnostic test targets COVID-19, the cause of the global health crisis affecting millions of people.

The underlying technology for Kantaro’s SARS-CoV-2 IgG Antibody Test Kit was developed at the Mount Sinai Health System, and manufactured and distributed by Bio-Techne. This groundbreaking antibody test kit reports the precise antibody levels in a patient’s bloodstream, ensuring accuracy, reliability and accessibility, as it uses an enzyme-linked immunosorbent assay (ELISA) format.

Accurate

  • Unlike other antibody tests, Kantaro’s kit reports the amount of titer found in the bloodstream in addition to a positive/negative determination, enabling a more accurate understanding of antibody presence.
  • Knowing the precise amount of titer in the bloodstream helps individuals, communities, employers and governments make informed decisions towards a healthier future.
  • The technology at the core of the test has been described by peer-reviewed publications like Nature, and granted an Emergency Use Authorization by the FDA and CE marking in the European Union, meaning it meets the highest international standards.

Proven

  • The Mount Sinai Health System’s Antibody Assay, the underlying technology in Kantaro’s antibody kit, was used during the height of the COVID-19 outbreak in New York City. Translating this technology into the commercial kit with the experience of Bio-Techne was vital to ensure accuracy and dependability, even in high-volume use cases.
  • As of October 2020, Mount Sinai has successfully used the underlying technology that now powers the Kantaro kit over 80,000 times, helping guide real-time treatment decisions.
  • Kantaro’s kits have the potential to be used in countless real-world applications, from guiding clinical decisions and policy making, to accelerating therapeutic treatments and vaccine development.

Accessible

  • Kantaro’s antibody tests require only ELISA capabilities to read, making them cost-effective, reliable and easily run by any high complexity laboratory — so they can be used across the country and around the world.
  • Kantaro’s tests help ensure that every community can access critical health information – including communities that have been disproportionately affected by COVID-19.
  • Kantaro has partnered with Bio-Techne to create a robust supply chain for tests, with the goal of enabling 20 million tests per month.
  • Kantaro offers patients the opportunity to add their data to Mount Sinai’s growing population-wide studies using a consistent testing method to the large data sets needed as a foundation for government policies.

The commercial test kits for clinical laboratories are available in the U.S. and CE-marked territories.

Key Collaborations

Kantaro has announced a partnership with Bio-Techne Corporation to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. The two companies have formed a joint commercialization and distribution team to support rapid distribution of the assay.  R&D Systems, a Bio-Techne brand, is a world leading ELISA developer and manufacturer.

Kantaro has also partnered with EKF Diagnostics for the marketing and distribution of COVID-SeroKlir and COVID-SeroIndex.

If you are interested in becoming a strategic partner, please visit For Partners